Investigating the use of 3D facial mapping technology as an effective screening tool to detectdementia-related diseases

Strong Room Technology Pty Ltd0 个研究点目标入组 75 人开始时间: 2020年8月14日最近更新: 2023年10月3日

试验速览

暂无简介。

•1. A diagnosis of dementia under the DSM-5 Criteria for Dementia for the dementia cohort using:
•1.1. Medical history
•1.2. Neuroimaging
•1.3. Neuropsychological assessment
•2. At least 8 years of education
•3. Normal cognition under standardised testing for the age-matched healthy controls

•1. Any significant facial deterioration through another disease or aetiology that could influence facial mapping or imaging
•2. Patient diagnosed with Mild-Cognitive Impairment (MCI)
•3. Patients diagnosed with mild memory impairment
•4. Patients diagnosed with psychiatric conditions such as schizophrenia (due to presence of cataracts, lens opacities or corneal pigmentation) Smith et al., 1997 aggravated by poor performance on visual tasks (Hess et al., 1997 and Silverstein et al., 2000; 2009, 2012)
•5. Patient diagnosed with neurological lesions such as cerebellar lesions as seen in Huntington’s, Wilson’s and Whipple Disease – can produce similar ocular hypometric, prolonged saccade latencies as seen in some types of dementia
•6. Patients with underlying dermatological conditions such as dermatomyositis – as important facial landmarks and anatomy can be altered

发起方

Strong Room Technology Pty Ltd